This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Adverse reactions frequently occur in patients with AIDS who are treated with trimethoprim-sulfamethoxazole (TMP/SMX) for Pneumocystis carinii pneumonia (PCP). Intolerance to sulfonamides is 10 times more common in HIV-infected patients than in the general population. [1] Dermatologic (rash, urticaria), gastrointestinal (nausea, vomiting, anorexia), and hematologic (leukopenia) side effects are most common. However, numerous adverse neurologic effects can occur, including headache, aseptic meningitis, ataxia, peripheral neuritis, seizures, hallucinations, and tremor. [2] All are potentially reversible with cessation of TMP/SMX or, in some cases, with only a dose reduction. I report a patient with AIDS treated with TMP/SMX for PCP who developed a marked postural and kinetic tremor without other stigmata of TMP/SMX-induced reactions, which resolved with its discontinuation.
Case report.
A 46-year-old man with a 6-year history of AIDS was evaluated for "shakes." He was on day 13 of TMP/SMX treatment (320 mg of trimethoprim and 1,600 mg of sulfamethoxazole three times daily) for PCP and had experienced increasing tremulousness over the preceding 10 days. His other medications included paroxetine, didanosine (ddI), prednisone, leucovorin, clotrimazole, and diazepam, none of which had been started recently. The tremor involved his head and all extremities, and he had noticed a precipitous …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Association of Neurofilament Light With the Development and Severity of Parkinson Disease
Dr. Rodolfo Savica and Dr. Parichita Choudhury
► Watch
Alert Me
Recommended articles
Is tremor in dystonia a phenotypic feature of dystonia?
Longitudinal follow-up with VIM thalamic deep brain stimulation for dystonic or essential tremor
Paroxysmal dyskinesias in patients with HIV infection
Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects